Biotechnology sits at an unusual crossroads in IP law, it deals in living systems, genetic material, and biological processes, all of which patent offices have historically treated with more caution than a purely synthetic invention. Understanding where the line falls between what’s patentable and what isn’t is often the first real strategic decision a biotech innovator has to make, well before drafting begins. This post walks through patentability in biotech, how the rest of the IP toolkit applies, where innovation is happening, and how PATHtoIP fits into that process.
What Makes a Biotechnology Invention Patentable
The Three Basic Tests
Biotech inventions still have to clear the same fundamental bar as any other field:
- Novelty: not already disclosed publicly, anywhere.
- Inventive step: not something a skilled person in the field would arrive at through routine work.
- Industrial applicability: capable of being made or used, with a specific, credible utility.
The Line Biotech Has to Navigate: Discovery vs. Invention
The core patentability challenge in biotech is that patent law generally excludes naturally occurring substances and processes as such, a gene as it exists in nature, or a naturally occurring microorganism, isolated but unmodified, is typically treated as a discovery rather than an invention. What tips something into patentable territory is usually human intervention: an isolated and purified sequence with a demonstrated, specific function; a genetically modified organism; a novel method of producing a biological product; or a diagnostic or therapeutic application built on top of a natural discovery.
India’s Patents Act adds explicit exclusions relevant here, plants and animals in whole or any part thereof (other than microorganisms), and essentially biological processes for their production, are not patentable under Section 3(j). This makes India meaningfully more restrictive than the US in areas like plant variety innovation, which is instead addressed through a separate Plant Varieties Protection framework rather than patents.
What Typically Gets Filed
- Genetically modified organisms and cell lines with a demonstrated application
- Novel methods: gene editing techniques, protein expression systems, fermentation processes
- Diagnostic methods: though method-of-diagnosis claims face restrictions in several jurisdictions, including India
- Novel biological products: recombinant proteins, engineered enzymes, vaccines
- Isolated sequences or compounds with a specific, non-obvious, disclosed function
Patentability Compared: India, the US, and Europe
Biotech is one of the fields where subject-matter exclusions diverge the most across jurisdictions, what’s flatly unpatentable in one country may be routinely granted in another.
| Issue | India | United States | Europe (EPO) |
| Governing law | Patents Act, 1970 | 35 U.S.C. (Patent Act) | European Patent Convention |
| Plants, animals, and essentially biological processes | Excluded under Section 3(j), other than microorganisms | Plants excluded from utility patents but covered by a separate Plant Patent Act / Plant Variety Protection Act; animals have been held patentable in limited circumstances (e.g., genetically modified) | Excluded under Art. 53(b) for plant/animal varieties and essentially biological processes, though microbiological processes and their products remain patentable |
| Isolated natural genes/sequences | Patentable only with demonstrated specific function and human intervention beyond mere isolation | Naturally occurring DNA sequences are not patentable per se (Myriad); synthetic cDNA can be | Isolated sequences can be patentable if industrial applicability/function is disclosed |
| Diagnostic methods on the human/animal body | Excluded from patentability | Assessed under the abstract-idea/law-of-nature framework (Mayo); often difficult to patent | Excluded under Art. 53(c) as methods of diagnosis practiced on the body |
| Microorganisms | Patentable | Patentable | Patentable |
| Examination | Request-based; can take several years unless expedited | Automatic upon filing; generally faster | Typically 3–4 years; opposition is a distinct, active post-grant risk |
The practical takeaway: claims built around plant traits, isolated natural sequences, or diagnostic methods often need to be reshaped entirely, sometimes into a different protection mechanism altogether, like Plant Variety Protection, depending on which jurisdiction they’re headed for.
Where Innovation Is Actually Happening
- Gene editing: CRISPR-based tools and their expanding therapeutic and agricultural applications
- Synthetic biology: engineered organisms designed for specific industrial or therapeutic outputs
- Cell and gene therapy: a fast-growing and heavily patented therapeutic category
- Industrial biotechnology: enzymes and microorganisms engineered for manufacturing, waste processing, or biofuels
- Agricultural biotechnology: engineered crop traits, though subject to the plant-related exclusions noted above in India
Given how fast this field moves and how much prior art now exists in gene-editing techniques specifically, a patentability search early in R&D is less optional here than in almost any other domain.
Protecting the Product from Every Angle
- Patents: protect genuinely inventive processes, modified organisms, and specific applications not natural discoveries as such.
- Trade secrets: often protect the fine-grained process know-how in fermentation, cell-line maintenance, or purification that’s difficult to reverse-engineer from the end product.
- Plant Variety Protection: (a separate regime from patents in India and many jurisdictions) covers new plant varieties where patents don’t reach.
- Trademarks: protect the commercial brand under which a biotech product or platform is sold.
- Material Transfer Agreements and licensing: aren’t IP registrations themselves but are essential contractual tools for controlling how biological materials move between collaborators, worth flagging even though they sit outside the patent system.
What This Means for Filing Strategy
- Draft claims around the human intervention and specific application, not the underlying natural material, to clear patentable-subject-matter objections.
- Anticipate India’s Section 3(j) exclusions early if plant- or animal-related biological processes are involved, these claims may need to be reshaped or redirected to plant variety protection instead.
- Build a clear, specific, credible utility into the specification for any isolated sequence or compound claim.
- Run a freedom-to-operate check before commercializing gene-editing-based products given how dense and actively litigated that patent landscape has become globally.
How PATHtoIP Helps
Biotech IP strategy often requires untangling patentable subject matter before drafting even starts. PATHtoIP supports biotech innovators across the full path:
- Patentability searches, with specific attention to subject-matter eligibility issues unique to biological inventions
- Freedom to Operate analysis, particularly relevant given how dense gene-editing and cell-therapy patent landscapes have become
- Patent drafting and filing for processes, modified organisms, and applications, in India and internationally
- Guidance on Plant Variety Protection where patent exclusions apply
- Technology landscape analysis to identify open research directions
Stay connected with PATHtoIP for the latest insights on patents, trademarks, copyrights, innovation, and IP strategy. Follow us on LinkedIn, Instagram, Facebook, X , Pinterest, YouTube, and Quora for expert guidance, industry updates, case studies, and practical tips to protect your innovations.
Frequently Asked Questions
Can you patent a gene in India or the US?
Generally, no, naturally occurring genes are excluded as products of nature in both countries. Modified constructs, like cDNA in the US, can be patentable, but isolated natural DNA sequences are not.
Are genetically modified organisms patentable in India?
Microorganisms can be patented if genuinely man-made. Plants and animals, and essentially biological processes for producing them, are excluded under Section 3(j).
Why does CRISPR licensing matter for a startup working on gene editing?
Foundational CRISPR patents are concentrated among a few institutions following a long-running dispute over who invented the technology first. A startup building on CRISPR typically needs a license from the relevant patent holder before commercializing, which makes an FTO check essential early on.
Working with a modified organism, process, or gene-editing application and not sure how it’s protected? PATHtoIP can help you map it out, reach out at info@pathtoip.com.
